## WST: West Pharmaceutical Services, I - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -1.0% below STRENGTH zone (3.0-6.0%); PEG 3.38 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($251.44)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. West Pharmaceutical Services (WST) Valuation Check After 19% Year-to-Date Share Price Decline**
- Source: Simply Wall Street | 20251214T040830 | Somewhat-Bullish | Relevance: 100%
- West Pharmaceutical Services (WST) has experienced a 19% year-to-date decline in its share price, prompting a reevaluation of its valuation. Despite this pullback, the company shows steady underlying growth driven by GLP-1 revenues and expected operational efficiencies from new automated lines. While a narrative fair value suggests it is undervalued at $346, another perspective indicates its P/E ratio is stretched compared to industry averages and peers.

**2. West Pharmaceutical Services (WST) Valuation Check After 19% Year-to-Date Share Price Decline**
- Source: Simply Wall Street | 20251214T033620 | Somewhat-Bullish | Relevance: 100%
- West Pharmaceutical Services (WST) has seen a 19% year-to-date share price decline, prompting a fresh valuation analysis. Despite this, the company exhibits steady underlying growth, with future growth opportunities projected to close the gap between its current price and a narrative fair value near $346. However, alternative views suggest its valuation based on earnings looks stretched compared to industry peers, indicating less margin for error.

**3. West Pharmaceutical Services (NYSE: WST) to present at J.P. Morgan Healthcare Conference**
- Source: Stock Titan | 20251212T110142 | Neutral | Relevance: 100%
- West Pharmaceutical Services (NYSE: WST) will present at the J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 9:00 am PST in San Francisco. A live webcast will be available in the Investors section of the company's website, with a replay accessible for approximately 90 days after the event. The company is a global leader in innovative solutions for injectable drug administration, headquartered in Exton, Pennsylvania.

**4. West Pharmaceutical Services declares quarterly dividend of $0.22 By Investing.com**
- Source: Investing.com Australia | 20251210T120008 | Bullish | Relevance: 100%
- West Pharmaceutical Services, Inc. has declared a regular quarterly dividend of $0.22 per share, continuing its 53-year streak of dividend payments and 33 consecutive years of dividend increases. The dividend is payable on February 4, 2026, to shareholders of record as of January 28, 2026. This announcement follows several analyst updates with positive outlooks and increased price targets for the company.

**5. West Declares Quarterly Dividend**
- Source: WSAV-TV | 20251210T060000 | Bullish | Relevance: 100%
- West Pharmaceutical Services, Inc. (NYSE: WST) has declared a regular quarterly dividend of $0.22 per share. The dividend will be payable on February 4, 2026, to shareholders of record as of January 28, 2026. The company is a global leader in solutions for injectable drug administration, supporting the safe delivery of medicines worldwide.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $285 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | init | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 2 ($0.14M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.9% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 7 |

**Top Holders:**
- Vanguard Group Inc: 13.5% (+4.2%)
- Blackrock Inc.: 9.0% (-2.3%)
- State Street Corpora: 4.5% (-1.9%)
- Bank Of New York Mel: 4.0% (-9.4%)
- Artisan Partners Lim: 3.9% (+22.2%)

### Key Risks

1. Valuation stretched: PEG 3.4x requires aggressive growth execution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 3.38 signals overvaluation risk, limited margin of safety. Forward P/E 34.4x stretched relative to 10% growth. Quality metrics strong (ROA 10%, margin 16%). Balance sheet: strong liquidity (2.9x), low leverage (D/E 0.35). Institutional flow bearish (7 selling vs 3 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $19.2B |
| Beta | 1.17 |
| 52W Range | $187.43 - $348.90 |
| Short Interest | 3.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.38 |
| Forward P/E | 34.4 |
| Current P/E | 37.7 |
| YoY Growth | 9.6% |
| EPS Direction | RISING |

### Technicals

MRS_10 strengthening from -3.8% to -1.0% (+2.8% in 5 days), confirming momentum buildup. Below STRENGTH zone by 4.0pp (needs >3.0% for momentum thesis). MRS_5 turning positive (1.0%) - potential reversal signal. Long-term uptrend intact (above SMA200 at 1.11x) but short-term weakness (below SMA20). MACD histogram bearish (-0.76), momentum weakening. RSI neutral at 46. OFD pattern: -MLN (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.00% (CS: 18) | Neutral |
| RSI_14 | 45.8 | Neutral |
| MACD Histogram | -0.76 | Bearish |
| vs SMA20 | 0.988x | Below |
| vs SMA50 | 0.978x | Below |
| vs SMA200 | 1.113x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $267.56
- **Stop Loss:** $251.44 (6.0% risk)
- **Target:** $283.68 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 62
- **Position Value:** $16,588.72
- **Portfolio %:** 16.59%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX remains calm at 15.74 while breadth shows modest participation at 54%, suggesting selective positioning. FOMC meeting in 4 days creates near-term uncertainty but no systemic stress evident.*

### Earnings

**Next:** 2026-02-12 (Est: $1.83)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.71 | $1.96 | +14.5% |
| 2025Q2 | $1.54 | $1.84 | +19.7% |
| 2025Q1 | $1.26 | $1.45 | +15.3% |
| 2024Q4 | $1.73 | $1.82 | +5.3% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*